Cagrilintide (CAG) is a long-acting amylin analog that is being studied for its potential to support appetite regulation and weight management. Amylin is a naturally occurring hormone released alongside insulin after meals that helps signal fullness, slows stomach emptying, and may reduce overall food intake. Cagrilintide works through a different biological pathway than GLP-1 medications, and researchers are investigating its use both alone and in combination with GLP-1 therapies because the two mechanisms may complement one another.
Potential areas of research include:
- Supports feelings of fullness (satiety)
- May help reduce appetite and portion sizes
- Slows gastric emptying
- Being studied for weight management and metabolic health
- Investigated in combination with GLP-1 therapies for enhanced effects